Montessa Lee, a small cell lung cancer (SCLC) survivor and advocate since 2006, discusses her SCLC journey, how she navigated her diagnosis at 28 years old, and how her story of survival – told through the “Nothing Small About It” program – can inspire others.
Dr. Debbie Thurmond, Ph.D., Director of the City of Hope’s Arthur Riggs Diabetes & Metabolism Research Institute discusses the institute’s focus on the intersection of diabetes and cancer, helping to answer the reasons why diabetes is significantly associated with an increase in cancer and how the growing number of highly effective cancer therapies may cause insulin-dependent diabetes. She also talks about how philanthropic support will drive more discovery for the diabetic patient community and address some of the biggest drivers of inequity across healthcare.
Dr. Michael Forbes, Pediatric & Adolescent Intensive Care Specialist and the Director of PICU Clinical Research & Outcomes Analysis at Akron Children’s Hospital, discusses respiratory syncytial virus (RSV), a common, contagious virus that causes flu-like illness in infants and toddlers, and the concern over the recent summer surge in cases. The CDC recently expressed particular concern that the pandemic has put babies and toddlers at risk for severe illness from RSV. He provides important details on what parents need to know about RSV, including which kids are at highest risk and how it can be prevented.
Allergist and immunologist Dr. Payel Gupta, professor at SUNY Downstate Medical Center and Mt. Sinai Medical Center, discusses differences between symptoms often seen with COVID-19 (including the latest Delta variant) compared to symptoms of a common cold and/or environmental allergies. Dr. Gupta outlines why it is critical to know the difference and at what point to consult a physician, in addition to ways to manage allergies as we head into another prime allergy season. Dr. Gupta is a paid spokesperson of ALK-Abello, Inc., a company that markets products to treat seasonal allergies including allergies to dust mites, grass and ragweed.
Tammy Krotz, 57, shares her experience contracting COVID-19. After being technically virus-free her condition worsened into what is being called “long COVID” or post-viral chronic fatigue syndrome. She is joined by Dr. Jacob Teitelbaum whose S.H.I.N.E.® protocol she says literally saved her life.
Gregory Wagner, CEO of RYAH Group, a publicly listed big data and technology company focused on valuable predictive analysis in the global medical plant intake industry discusses the significance of data in the cannabis industry and why companies leading with data will be golden in the cannabis sector. While RYAH offers many different IoT products/devices such as smart inhalers, smart-pens and smart-patches that provide accurate and calculated dosing for individual patients according to their conditions, the proprietary IoT devices are agnostic to the type of medicine, delivery method and are a gateway for delivery and analysis of valuable data. RYAH’s proprietary software platform captures rare and complex data that is invaluable for clinics, physicians, and regulators and enable them to make better and more informed decisions for the industry as a whole.
David Elsley, MBA, President and CEO of Cardiol Therapeutics, Inc., a clinical stage biotech, discusses the Company’s research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). David talks about the Company’s lead product, CardiolRx™ a pharmaceutically produced oral cannabidiol formulation that has entered a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus who have a prior history of, or risk factors for, CVD. With the Delta variant spreading quickly, there is an urgent need to treat these high-risk patients. Cardiol is also planning to file an investigational new drug (“IND”) application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age.
Sheri Mullen, Senior Vice President, Specialty Business Unit, US Pharma at GSK discusses BENLYSTA (belimumab), the first and only biologic approved for lupus and lupus nephritis in adults, and its decade-in-market milestone. She shares insights around GSK leadership in reducing progression of long-term organ damage with BENLYSTA’s proven efficacy, investing in comprehensive lupus programs and clinical trials, revolutionizing the stagnant lupus landscape, and engaging lupus patient and advocacy communities to build trust and gain insights to better understand patient and caregiver needs and more.
Dr. Edio Zampaglione, Head of Global Medical Affairs and Outcomes Research at Organon and an OBGYN, discusses unintended pregnancies, the importance of starting conversations about birth control options with college-bound students, and a new study published in “Pediatrics” that shows that conversations with adolescents about sexual and reproductive health, other than puberty, aren’t routinely taking place during preventive care visits, even though 72% of 15-17-year-olds (and 78% of parents of 15-17-year-olds) consider discussions about methods of birth control important.
Returning guest, board-certified internist, Dr. Jacob Teitelbaum, MD, discusses the recently released (June 2021) 4th edition of his book “From Fatigued to Fantastic: A Clinically Proven Program to Regain Vibrant Health and Overcome Chronic Fatigue and Fibromyalgia” that now offers critical support for those with “long-hauler” syndrome following COVID-19 as well as new strategies for managing chronic fatigue and pain.